Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Trastuzumab
Herceptin · 1 trial · 1 indication
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
| Arm | Type | Description |
|---|---|---|
| HER2+ | EXPERIMENTAL | Human Epidermal growth factor Receptor 2 positive (HER2+): Gemcitabine + Carboplatin + Herceptin. |
| HER2- (Taxane-) | EXPERIMENTAL | Human Epidermal growth factor Receptor 2 negative (HER2-): Gemcitabine + Carboplatin. (Taxane-naive patients). |
| HER2- (Taxane+) | EXPERIMENTAL | Human Epidermal growth factor Receptor 2 negative (HER2-): Gemcitabine + Carboplatin. (Taxane-pretreated patients). |
| Name | Type | Description |
|---|---|---|
| Gemcitabine | DRUG | Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion) |
| Carboplatin | DRUG | Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion). |
| Herceptin | DRUG | Day 1 of 14 day cycle (Cycle 1): 8 milligrams per kilogram (mg/kg) intravenous (IV) (90 minute infusion). Day 1 of 14 day cycle (Cycles 2-9): 4 mg/kg IV (30 minute infusion). Day 1 of 21 day cycle (Cycles 10+): 6 mg/kg IV (30 minute infusion). |
Inclusion Criteria: 1. Diagnosis of metastatic breast cancer 2. Able to visit the doctor's office at least every 14 days during the actual treatment 3. Able to care for yourself, even if you cannot work or participate in other normal activities 4. Your blood results must be adequate for therapy. 5....
Top 20 of 92 competitors
Herceptin is used for the treatment of breast cancer, specifically in patients with metastatic breast cancer who are human epidermal growth factor receptor 2 positive (HER2+). It is being studied in combination with gemcitabine and carboplatin in a clinical trial setting.
Herceptin targets the human epidermal growth factor receptor 2 (HER2). It is a monoclonal antibody (-mab) that binds to HER2, which is overexpressed in some breast cancers. This targeting is relevant for HER2-positive metastatic breast cancer patients.
Herceptin is being developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The company is conducting clinical research on this drug for breast cancer.
Herceptin is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, with no active trials currently ongoing.
Herceptin has been studied in one clinical trial with the identifier NCT00191451. This Phase 2 trial, titled 'A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer,' enrolled 150 participants in the United States and has been completed.
Yes, Herceptin is also known as Trastuzumab. Both names refer to the same drug, which is a monoclonal antibody used in the treatment of HER2-positive breast cancer. Patients and healthcare providers may use either name interchangeably.